Peter F. Lebowitz

7.3k total citations · 1 hit paper
40 papers, 3.2k citations indexed

About

Peter F. Lebowitz is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Peter F. Lebowitz has authored 40 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Peter F. Lebowitz's work include Melanoma and MAPK Pathways (10 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Cancer-related Molecular Pathways (5 papers). Peter F. Lebowitz is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Cancer-related Molecular Pathways (5 papers). Peter F. Lebowitz collaborates with scholars based in United States, Australia and Netherlands. Peter F. Lebowitz's co-authors include George C. Prendergast, Richard Kefford, Georgina V. Long, Michael P. Brown, Wei Du, Joseph P. Davide, Steven O’Day, Anna C. Pavlick, Gerald S. Falchook and Jeffrey R. Infante and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Peter F. Lebowitz

40 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter F. Lebowitz United States	24	2.3k	1.8k	422	411	281	40	3.2k
Piro Lito United States	14	2.0k 0.8×	1.3k 0.7×	354 0.8×	647 1.6×	190 0.7×	30	2.7k
Martin L. Sos Germany	19	2.2k 0.9×	1.3k 0.7×	456 1.1×	995 2.4×	164 0.6×	34	3.2k
Danan Li United States	16	2.3k 1.0×	1.6k 0.9×	496 1.2×	1.0k 2.5×	251 0.9×	21	3.2k
Gatien Moriceau United States	21	2.2k 0.9×	1.5k 0.8×	406 1.0×	297 0.7×	239 0.9×	25	2.8k
Kimberly B. Dahlman United States	21	2.3k 1.0×	1.7k 0.9×	575 1.4×	460 1.1×	225 0.8×	38	3.2k
Paul Wan United Kingdom	9	1.9k 0.8×	991 0.6×	228 0.5×	226 0.5×	208 0.7×	9	2.5k
Ensar Halilovic United States	19	1.8k 0.8×	977 0.5×	256 0.6×	375 0.9×	373 1.3×	33	2.3k
J.M. Ostrem United States	6	1.9k 0.8×	818 0.5×	225 0.5×	301 0.7×	210 0.7×	8	2.4k
Vanessa Rodrik-Outmezguine United States	16	2.1k 0.9×	943 0.5×	458 1.1×	561 1.4×	164 0.6×	32	2.8k
Therese M. Becker Australia	31	1.5k 0.7×	1.3k 0.7×	752 1.8×	408 1.0×	203 0.7×	89	2.6k

Countries citing papers authored by Peter F. Lebowitz

Since Specialization

Citations

This map shows the geographic impact of Peter F. Lebowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter F. Lebowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter F. Lebowitz more than expected).

Fields of papers citing papers by Peter F. Lebowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter F. Lebowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter F. Lebowitz. The network helps show where Peter F. Lebowitz may publish in the future.

Co-authorship network of co-authors of Peter F. Lebowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Peter F. Lebowitz. A scholar is included among the top collaborators of Peter F. Lebowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter F. Lebowitz. Peter F. Lebowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilkerson, Julia, Kald Abdallah, Mace L. Rothenberg, et al.. (2016). Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. The Lancet Oncology. 18(1). 143–154. 49 indexed citations

Falchook, Gerald S., Georgina V. Long, Razelle Kurzrock, et al.. (2014). Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 20(17). 4449–4458. 51 indexed citations

Nathanson, Katherine L., Anne‐Marie Martin, Bradley Wubbenhorst, et al.. (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 19(17). 4868–4878. 132 indexed citations

Carlino, Matteo S., Catherine A.B. Saunders, Lauren E. Haydu, et al.. (2012). 18F-labelled fluorodeoxyglucose–positron emission tomography (FDG–PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer. 49(2). 395–402. 36 indexed citations

Falchook, Gerald S., Georgina V. Long, Razelle Kurzrock, et al.. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet. 379(9829). 1893–1901. 719 indexed citations breakdown →

Bauman, John W., Joyce Antal, Laurel M. Adams, et al.. (2010). Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Investigational New Drugs. 30(2). 662–671. 6 indexed citations

Johnson, Brendan M., Laurel M. Adams, Ke Zhang, et al.. (2010). Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin‐1 Receptor Antagonist. The Journal of Clinical Pharmacology. 50(8). 951–959. 13 indexed citations

Adams, Laurel M., Brendan M. Johnson, Ke Zhang, et al.. (2009). Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Supportive Care in Cancer. 17(9). 1187–1193. 7 indexed citations

Johnson, Brendan M., et al.. (2009). Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Supportive Care in Cancer. 17(9). 1177–1185. 14 indexed citations

10.

Korde, Larissa A., Lara Lusa, Lisa M. McShane, et al.. (2009). Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Research and Treatment. 119(3). 685–699. 79 indexed citations

11.

Curtis, Kelly K., Roxanne C. Jewell, Peter F. Lebowitz, et al.. (2009). A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m²Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer. The Journal of Clinical Pharmacology. 50(3). 268–275. 7 indexed citations

12.

Storniolo, Anna Maria, Mark D. Pegram, Beth Overmoyer, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology. 26(20). 3317–3323. 89 indexed citations

13.

Rapkiewicz, Amy, Virginia Espina, Jo Anne Zujewski, et al.. (2007). The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 111(3). 173–184. 65 indexed citations

14.

Waes, Carter Van, Angela A. Chang, Peter F. Lebowitz, et al.. (2005). Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology*Biology*Physics. 63(5). 1400–1412. 93 indexed citations

15.

Chang, Angela A., Barbara A. Conley, Peter F. Lebowitz, et al.. (2004). Bortezomib with Concurrent Radiation Therapy in Head and Neck Squamous Cell Carcinoma. Otolaryngology. 131(2). 1 indexed citations

16.

Lebowitz, Peter F. & George C. Prendergast. (1998). Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17(11). 1439–1445. 179 indexed citations

17.

Lebowitz, Peter F., et al.. (1998). Functional interaction between RhoB and the transcription factor DB1. Cell adhesion and communications/Cell adhesion and communication/Cell adhesion & communication. 6(4). 277–287. 30 indexed citations

18.

Lebowitz, Peter F., Wei Du, & George C. Prendergast. (1997). Prenylation of RhoB Is Required for Its Cell Transforming Function but Not Its Ability to Activate Serum Response Element-dependent Transcription. Journal of Biological Chemistry. 272(26). 16093–16095. 75 indexed citations

19.

Prendergast, George C., Joseph P. Davide, Peter F. Lebowitz, Robert J. Wechsler‐Reya, & Nancy E. Kohl. (1996). Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.. PubMed. 56(11). 2626–32. 39 indexed citations

20.

Lebowitz, Peter F., Joseph P. Davide, & George C. Prendergast. (1995). Evidence that Farnesyltransferase Inhibitors Suppress Ras Transformation by Interfering with Rho Activity. Molecular and Cellular Biology. 15(12). 6613–6622. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact